抗艾滋病新药BIKTARVY的药理作用及临床评价

Pharmacological effect and clinical evaluation of BIKTARVY,a new anti-AIDS drug

BIKTARVY是由比替拉韦、恩曲他滨和富马酸丙酚替诺福韦3种成分组成的口服复合制剂。该药被视为是治疗Ⅰ型艾滋病病毒(HIV-1)感染的完整方案,被批准用于治疗未经治疗或取得完全病毒学抑制3个月以上、没有耐药史、没有治疗失败史的HIV-1感染者。现对本药的药理作用、药动学、临床及安全性评价和药物相互作用等做一综述。

BIKTARVY is a three-drug fixed dose combination product containing bictegravir,emtricitabine,and tenofovir alafenamide.BIKTARVY is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1(HIV-1)infection in adults without antiretroviral treatment history or replace the current antiretroviral regimen in those virologically-suppressed(HIV-1 RNA less than 50 copies per mL)on a stable antiretroviral regimen for at least 3 months,with no history of treatment failure and no known substitutions associated with resistance to the individual components of BIKTARVY.In this review,we summarized the pharmacological mechanism,pharmacokinetics,clinical evaluations,side effects and drug interactions.